Clinical Trials Logo

Colorectal Cancer clinical trials

View clinical trials related to Colorectal Cancer.

Filter by:

NCT ID: NCT05506696 Completed - Colorectal Cancer Clinical Trials

Vitamin D Supplementation Study

Start date: September 24, 2012
Phase: N/A
Study type: Interventional

Patients with colorectal cancer will be recruited to undergo vitamin D supplementation in the peri-operative period. Vitamin D levels (25OHD) will be measured to assess response to supplementation.

NCT ID: NCT05502666 Completed - Colorectal Cancer Clinical Trials

¡Salud! Por la Vida (SPLV) A Colorectal Screening Promotion Program

SPLV
Start date: July 8, 2017
Phase: N/A
Study type: Interventional

The overall goal of this educational program was to increase colorectal cancer screening (CRCS) in men and women who attend Federally Qualified Health Centers (FQHC) in Puerto Rico. FQHCs, referred to in Puerto Rico as "Clínicas 330", are ideal settings to implement innovative approaches to increase CRCS because they serve primarily low-income patients who typically have lower rates of screening. The goal of this study, is to develop and evaluate the impact of a clinic level intervention on increasing CRCS among low-income Puerto Rican men and women aged 50-75, who have either never been screened for colorectal cancer, or are under-screened according recommended guidelines. To evaluate the delivery of the CRCS education program we used a group randomized controlled trial that provided data to determine the effectiveness of the CRC intervention program compared with usual practice (no intervention).

NCT ID: NCT05501379 Recruiting - Colorectal Cancer Clinical Trials

Comparison of the Physical Activity in Cancer Patients Assessed by Questionnaire and Motion Tracker

OncoPhys
Start date: September 21, 2022
Phase:
Study type: Observational

Physical activity is an important aspect of cancer therapy but correct measurement of physical activity is difficult. In this study, the physical activity of patients undergoing cancer therapy is assessed by questionnaire and by motion tracker. The results are then compared to answer whether there are differences between the two measurements. Findings of this study will help to improve the assessment of physical activity in cancer patients.

NCT ID: NCT05500508 Recruiting - Breast Cancer Clinical Trials

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Start date: November 29, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.

NCT ID: NCT05497336 Recruiting - Colorectal Cancer Clinical Trials

A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer

Start date: August 18, 2022
Phase: Phase 1
Study type: Interventional

Phase 1b consists of combined dose escalation phase and dose expansion phase. Phase 3 study will compare efficacy and safety of IBI351 combined with cetuximab versus chemotherapy in treatment of KRAS G12C-mutated metastatic colorectal cancer

NCT ID: NCT05495776 Recruiting - Colorectal Cancer Clinical Trials

Prospective Multicenter Registry Study to Assess the Frequency of Lynch Syndrome Among Patients With Colorectal Cancer

MSIRus22
Start date: August 1, 2022
Phase:
Study type: Observational [Patient Registry]

Prospective multicenter registry study to assess the frequency of Lynch syndrome among patients with colorectal cancer in Russia

NCT ID: NCT05494658 Recruiting - Colorectal Cancer Clinical Trials

Impact of Preoperative Oral Branched-chain Amino Acids on Reducing Postoperative Insulin Resistance.

Start date: August 26, 2022
Phase: N/A
Study type: Interventional

Postoperative insulin resistance refers to the phenomenon that the body's glucose uptake stimulated by insulin is reduced due to stress effects such as trauma or the inhibitory effect of insulin on liver glucose output is weakened after surgery. There is a clear link between postoperative insulin resistance and poor perioperative prognosis. Therefore, exploring interventions to reduce postoperative stress insulin resistance, stabilize postoperative blood glucose, and reduce postoperative complications are clinical problems that need to be solved urgently. In recent years, research on branched-chain amino acids and metabolic diseases has become a hot spot. Studies have found that in the rat model, preoperatively given a high branched-chain amino acid diet can inhibit postoperative insulin resistance and stabilize blood glucose levels. This research plan is to try to add branched-chain amino acids before surgery to observe the occurrence of postoperative insulin resistance in patients.

NCT ID: NCT05492682 Recruiting - Colorectal Cancer Clinical Trials

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Start date: February 2, 2023
Phase: Phase 1
Study type: Interventional

This study is being conducted to explore the immunological mechanism of action of Peptide-coated Conditionally Replicating Adenovirus-1 (PeptiCRAd-1) plus Checkpoint inhibitor (CPI) therapy in multiple cancer types, as well as to obtain early information on the safety of this combination therapy.

NCT ID: NCT05489211 Recruiting - Colorectal Cancer Clinical Trials

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Start date: September 6, 2022
Phase: Phase 2
Study type: Interventional

TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

NCT ID: NCT05485974 Recruiting - Cancer Clinical Trials

A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

Start date: August 1, 2022
Phase: Phase 1
Study type: Interventional

A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.